Recombinant BCG vaccine - Aeras Global TB Vaccine Foundation/ UCLA

Drug Profile

Recombinant BCG vaccine - Aeras Global TB Vaccine Foundation/ UCLA

Alternative Names: rBCG30; recombinant Bacillus Calmette-Guerin 30

Latest Information Update: 31 Jan 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of California at Los Angeles
  • Class Synthetic vaccines; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Tuberculosis

Most Recent Events

  • 31 Jan 2007 No development reported - Phase-I for Tuberculosis in USA (unspecified route)
  • 02 Mar 2004 Phase-I clinical trials in Tuberculosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top